Clinical work for new mCRC therapy
COPENHAGEN, Denmark—Bavarian Nordic A/S has announced a Phase 2 study to evaluate the combination of CV301, its cancer vaccine, with Bristol-Myers Squibb’s nivolumab (Opdivo) in patients with metastatic colorectal cancer (mCRC). The trial will enroll up to 74 individuals with oligometastatic, microsatellite stable mCRC eligible for complete resection. Prior to surgery, participants will receive four cycles of either chemotherapy plus nivolumab or a combination of chemotherapy, nivolumab and CV301. Following surgery, patients will continue to receive their respective treatments. The trial is expected to begin enrollment before mid-year, and will be the four clinical combination of CV301 with a checkpoint inhibitor.
“To date, there are no checkpoint inhibitors approved for the treatment of microsatellite stable colorectal cancer. This trial marks an important step in exploring indications where checkpoint inhibitors have not been successful as a monotherapy,” said Paul Chaplin, president and CEO of Bavarian Nordic.